The organ sparing management of a patient with urachus cancer in conditions of comorbidity

Malignant tumors of the urachus are extremely rare. The frequency of urachal malignancy makes 1: 5 000 000 cases, which is 0.35–1.2 % of all the cases of bladder cancer. The small series of observations described in the literature do not allow us to formulate statistically reliable and unambiguously recommended statements about the optimal methods of diagnostics and treatment of this pathology. The diagnosis of urachus diseases is often challenging. This is associated with both the asymptomatic course and the variety of clinical flow of the disease. The treatment strategies are also largely ambiguous and ranging from the defining the indications for surgical treatment to the aggressiveness of surgical intervention. Meanwhile, 20 % of patients with urachal cancer have distant metastases at the time of detection. With everything listed above, (low frequency, little research done and aggressiveness of the flow) it makes every clinical observation of this disease valuable.

This article is a clinical observation providing with the information upon the diagnosis, the choice of strategies and surgical treatment of urachal cancer in a patient suffering from multimorbidity. Volumetric formation of the bladder was detected in this patient during additional examination for macrohematuria. Cystoscopy with transurethral resection and subsequent morphological examination verified invasive mucinous adenocarcinoma of the bladder with the growth into the lamina propria and without the signs of vascular and perineural invasion. The patient underwent laparotomy, radical resection of the bladder with extended pelvic lymphadenectomy. The umbilicus, urachus and the bladder wall with the tumor, as well as the adjacent peritoneum, were excised as a single block during the surgical intervention. Morphological examination verified mucinous adenocarcinoma of urachus. The postoperative period was uneventful.

There have been no signs of disease progression observed during 10-month follow-up period.

1. Loizzo D, Pandolfo SD, Crocerossa F, Guruli G, Ferro M, Paul AK, et al. Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice. Eur Urol Open Sci. 2022 Mar 14;39:1–6. https://doi.org/10.1016/j.euros.2022.02.009

2. Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA. The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol. 2012 Oct;188(4):1102–1107. https://doi.org/10.1016/j.juro.2012.06.020

3. Nyushko KM, Alekseev BYa, Kaprin AD. Clinical observation of organ preservation surgical treatment of the patient having urachus carcinoma. Medical Almanac. 2015;2(37):53–57. (In Russ.).

4. Kim IK, Lee JY, Kwon JK, Park JJ, Cho KS, Ham WS, et al. Prognostic factors for urachal cancer: a bayesian model-averaging approach. Korean J Urol. 2014 Sep;55(9):574–580. https://doi.org/10.4111/kju.2014.55.9.574

5. Shchedrov DN, Shormanov IS, Kotov SV, Morozov EV. Diagnosis and treatment of diseases caused by anomalies of urachus obliteration in children. Moscow: Pero Publishing House, 2021, 107 p. (In Russ.).

6. Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, et al. Current Understanding of Urachal Adenocarcinoma and Management Strategy. Curr Oncol Rep. 2020 Jan 27;22(1):9. https://doi.org/10.1007/s11912-020-0878-z

7. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol. 1984 Jan;131(1):1–8. https://doi.org/10.1016/s0022-5347(17)50167-6

8. Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and longterm outcomes of an aggressive malignancy. Cancer. 2006 Aug 15;107(4):712–720. https://doi.org/10.1002/cncr.22060

9. Pinthus JH, Haddad R, Trachtenberg J, Holowaty E, Bowler J, Herzenberg AM, et al. Population based survival data on urachal tumors. J Urol. 2006 Jun;175(6):2042–2047; discussion 2047. https://doi.org/10.1016/s0022-5347(06)00263-1

10. Shao G, Xu C, Liu J, Li X, Li L, Li X, et al. Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma. Urol Int. 2022;106(2):199–208. https://doi.org/10.1159/000518028

11. Szarvas T, Módos O, Niedworok C, Reis H, Szendröi A, Szász MA, Nyirády P. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urol Oncol. 2016 Sep;34(9):388–398. https://doi.org/10.1016/j.urolonc.2016.04.012

12. Helsby R. Ruptured infected urachal cyst. Br Med J. 1955 Sep 3;2(4939):603. https://doi.org/10.1136/bmj.2.4939.603

13. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec;46(12):1808–1814. https://doi.org/10.1016/j.humpath.2015.07.021

14. Cinar NB, Yilmaz H, Avci IE, Cakmak K, Teke K, Dillioglugil O. Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria. World J Surg Oncol. 2023 Feb 23;21(1):58. https://doi.org/10.1186/s12957-023-02943-9

15. Mayr R, Fritsche HM, Pycha A, Pycha A. Radical cystectomy and the implications of comorbidity. Expert Rev Anticancer Ther. 2014 Mar;14(3):289–295. https://doi.org/10.1586/14737140.2014.868775

16. Duan F, Zhai W, Zhang B, Guo S. Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes. Cancer Med. 2020 Jun;9(12):4166–4174. https://doi.org/10.1002/cam4.3059

17. Nyushko KM, Alekseev BYa, Kalpinsky AS, Kaprin AD. Urachal cancer. P.A. Herzen Journal of Oncology. 2015;4(3):43–47. (In Russ.).

18. Kunafina RI, Sakaeva DD, Urmantsev MF, Suleymanova RR. Clinical case of the use of a combination of paclitaxel and carboplatin in the treatment of metastatic urachus tumor. Farmateka. 2020;27(11):73–76. (In Russ.). https://doi.org/10.18565/pharmateca.2020.11.73-76